{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"A standard 3+3 dose-escalation design was used during dose escalation period. DLT was defined in protocol section 5.5.","groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg weekly.\n\nPembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells\n\nTrebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen","id":"OG000","title":"[Dose Escalation Dose Level I] Pembrolizumab + Trebananib"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.\n\nPembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells\n\nTrebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen","id":"OG001","title":"[Dose Escalation Dose Level II] Pembrolizumab + Trebananib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLTs will be monitored and collected for treated participants that enrolled during the dose escalation period.","reportingStatus":"POSTED","timeFrame":"3 weeks","title":"Number of Participants Experienced Dose Limit Toxicities (DLT)","type":"PRIMARY","unitOfMeasure":"Participants"}